REG - C4X Discovery - Total Voting Rights

C4X Discovery HoldingsAnnouncement

01/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230901:nRSA0096La&default-theme=true

RNS Number : 0096L  C4X Discovery Holdings PLC  01 September 2023

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Total Voting Rights

 

 

1 September 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, announces that for the purposes of the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules, the Company's issued
share capital consists of 252,227,097 ordinary shares.

 

The above figure of 252,227,097 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

 

- Ends -

 

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

 

C4X Discovery ("C4XD") is a pioneering Drug Discovery company, combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world‑leading medicines.  We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced candidate
molecule design and patient stratification capabilities, generating small
molecule drug candidates across multiple disease areas focused on
immuno-inflammation.  Our commercially attractive portfolio ranges from
early-stage target opportunities to late-stage Drug Discovery programmes and
we have three commercially partnered programmes with one candidate in clinical
development.

 

For more information visit us at www.c4xdiscovery.com
(http://www.c4xdiscovery.com/)  or follow us on twitter @C4XDiscovery.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRNKDBQPBKDDFN